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Background: The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids
necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme
of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently
been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether
HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free
survival (DFS).
Methods: A population-based cohort of primary breast cancer patients in Lund, Sweden was assembled between
October 2002 and June 2012 enrolling 1,116 patients. Tumor tissue microarrays were constructed and stained
with a polyclonal HMGCR antibody (Cat. No HPA008338, Atlas Antibodies AB, Stockholm, Sweden, diluted 1:100)
to assess the HMGCR expression in tumor tissue from 885 patients. HMGCR expression was analyzed in relation to
patient- and tumor characteristics and disease-free survival (DFS) with last follow-up June 30th 2014.
Results: Moderate/strong HMGCR expression was associated with less axillary lymph node involvement, lower
histological grade, estrogen and progesterone receptor positivity, HER2 negativity, and older patient age at
diagnosis compared to weak or no HMGCR expression. Patients were followed for up to 11 years. The median
follow-up time was 5.0 years for the 739 patients who were alive and still at risk at the last follow-up. HMGCR
expression was not associated with DFS.
Conclusion: In this study, HMGCR expression was associated with less aggressive tumor characteristics. However,
no association between HMGCR expression and DFS was observed. Longer follow-up may be needed to evaluate
HMGCR as prognostic or predictive marker in breast cancer.
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PrognosisIntroduction
New prognostic and treatment-predictive markers are
needed to improve treatment decisions and consequently
prognosis and treatment response in breast cancer
patients. Recent data suggest that the enzyme 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCR), which
is inhibited by statins that are commonly used as a* Correspondence: helena.jernstrom@med.lu.se
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unless otherwise stated.cholesterol-lowering treatment, may be associated with
breast tumor characteristics, prognosis and treatment
response [1–3]. HMGCR is the rate-limiting enzyme in
the mevalonate pathway [4]. The mevalonate pathway
produces cholesterol, steroid hormones, and non-steroid
isoprenoids, which are necessary for cell survival [5].
Previous studies demonstrated that HMGCR inhibitors
(e.g., statins) exert anti-carcinogenic effects by inducing
apoptosis and inhibiting inflammation [6], proliferation
and migration [7–9]. HMGCR inhibitors can also inhibit
angiogenesis [10]. Whether statins also reduce the risk ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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expressed among breast cancers, as well as between nor-
mal epithelial cells and tumor cells, with higher expression
in the tumor cells. This difference is presumably caused by
resistance against the feedback system of the mevalonate
pathway [18]. Several studies examined the relationship
between tumor-specific HMGCR expression and other
tumor characteristics [1, 2]. In previous studies, stronger
expression of HMGCR was associated with a less aggres-
sive tumor profile, such as a low histological grade, a small
tumor size, estrogen receptor (ER) positivity, and low pro-
liferation [1, 2]. One study reported that patients with
HMGCR-positive tumors exhibited longer recurrence-free
survival, which was more pronounced in patients with
ER-positive tumors [2]. Another study observed longer
recurrence-free survival in patients treated with tamoxifen
who had HMGCR-positive and ER-positive tumors com-
pared to patients who had ER-positive and HMGCR-
negative tumors, indicating that HMGCR may predict
tamoxifen response [3].
Hypothesis and aim
We hypothesized that stronger HMGCR expression was
associated with markers of good prognosis and prolonged
disease-free survival (DFS), as well as a better response to
tamoxifen, in this population-based unselected cohort of
primary breast cancer patients. The aims of the study were
to investigate whether HMGCR expression in breast can-
cer was associated with patient and tumor characteristics,
prognosis and treatment response.
Materials and methods
Patients
Women diagnosed with a primary breast cancer at Skåne
University Hospital in Lund, Sweden between October
2002 and June 2012 were invited to take part in an
ongoing prospective cohort study: the Breast Cancer (BC)
Blood study. During the inclusion period, 1,116 patients
were included in the study and followed-up until June
30th, 2014. Patients with a previous breast cancer diagnosis
or another cancer diagnosis during the previous ten years
were not included. The aim was to study factors that could
affect prognosis or treatment response and to identify new
markers that may help better tailor adjuvant therapy to
individual breast cancer patients. The study was approved
by Lund University Ethics Committee (Dnr LU75-02,
LU37-08, LU658-09, LU58-12, and LU379-12). All patients
signed a written informed consent. The study adhered
to the REMARK criteria [19].
All patients completed questionnaires preoperatively.
Post-operative questionnaires were completed after 3–6
months, 7–9 months, and 1, 2, 3, 5, 7, 9 and 11 years. The
questionnaires included questions concerning medication
intake during the last week, lifestyle, and reproductivefactors. Medications were coded according to the Ana-
tomic Therapeutic Chemical (ATC) classification system
codes [20]. Patients who reported smoking during the last
week or smoking at parties were considered current
smokers. Coffee consumption was categorized as 0–1 or
2+ cups/day, as previously described [21]. A research
nurse obtained body measurements, including, height,
weight, waist and hip circumferences, and breast volumes,
at the pre-operative visit. Breast volume was measured as
previously described [22, 23].
Tumor characteristics were acquired from the patients’
pathology reports. The estrogen receptor (ER) and proges-
terone receptor (PgR) expression were analyzed in the
Department of Pathology at Skåne University Hospital in
Lund, Sweden. Until December 2009, immunohistochem-
istry was performed using the Dako LSAB kit system
(Dako, Glostrup, Denmark) and the M7047 (ER) and
M3569 (PgR) antibodies (DAKO) [24, 25]. From 2010
onwards, the ER (SP1) and PgR (1E2) antibodies from
Ventana Medical Systems (Ventana, AZ, USA) were used
in combination with a Ventana Benchmark Ultra instru-
ment (Ventana Medical Systems) [26]. Tumors with more
than 10 % positive nuclear staining were considered ER-
positive or PgR-positive according to current Swedish clin-
ical guidelines. Histological type was classified into ductal,
lobular and ‘other’ types. Ten tumors had a mixed ductal
and lobular histology and were classified as ‘other’. Since
the tumors were not routinely analyzed for HER2 amplifi-
cation until November 2005, patients included in the
study prior to that time were excluded from analyses that
included HER2 status.
Information on type of surgery, treatment, and breast
cancer related events was obtained from patient charts
and the regional tumor registry. The date of death was
collected from the Swedish Population Registry. Patients
who had received preoperative treatment (n = 51) and
patients with cancer in situ (n = 39) were excluded from
the analyses, leaving 1,026 preoperatively untreated pa-
tients with invasive breast cancer as the study popula-
tion (Fig. 1).
Tissue microarray construction
Tumor tissue was available from 992 of the 1,026 patients.
Tissue microarrays (TMAs) for the tumors were con-
structed by sampling 1 mm duplicate cores from represen-
tative, non-necrotic tumor regions from the donating
formalin-fixed paraffin-embedded tumor tissue block from
surgical resection, using a semi-automated tissue array
device (Beecher Instruments, Sun Prairie, WI, USA).
Immunohistochemistry
An automatic PT-link system (DAKO, Glostrup, Denmark)
was used to deparaffinize and pretreat 4 μm TMA-sections
for HMGCR staining. HMGCR staining was performed
1116 patients included in the study
51 patients excluded due to 
pre-operative treatment
39 patients excluded due to in 
situ carcinoma1026 patients analyzed for patient-
and tumor characteristics
TMA constructed for 992 patients
TMA from 885 patients evaluable for 
scoring
877 patients analyzed for disease-
free survival
8 patients excluded due to 
metastatic breast cancer within 
three months of inclusion 
TMA from 107 patients not 
evaluable for scoring due to 
fat, connective tissue, 
dislocation/process damage, in 
situ carcinoma, or normal 
breast tissue
Fig. 1 Flow chart of the patient selection process
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instructions (DAKO). The staining procedure employed an
HMGCR antibody (Cat. No HPA008338, Atlas Antibodies
AB, Stockholm, Sweden) (diluted 1:100) and an EnVision
FLEX high-pH kit. HMGCR expression could be evaluated
in tumors from 885/992 patients. In 57 cases, the TMA-
cores contained non-representative tissue, in 27 cases, the
cores were damaged or lost during processing, and in 23
cases, the cores could not be evaluated due to a combin-
ation of the reasons mentioned above. HMGCR expres-
sion was evaluated based on the staining intensity in the
cytoplasm (i.e., negative = 0, weak = 1, moderate = 2, and
strong = 3), as shown in Fig. 2, and based on the fraction
of HMGCR-positive cells (0 % = 0, 1-10 % = 1, 11-50 % =
2, 51-100 % = 3). Two investigators, who were blinded to
the patient data and clinical outcome, evaluated all sam-
ples simultaneously (EG, HT). When the two investigators
could not reach a consensus, a senior investigator (SB)
was consulted and a consensus was reached. The HMGCR
expression differed between the duplicate cores for 109
patients. In all cases but one, the intensity only differed by
one step. Discordant cores were reevaluated jointly to ob-
tain a pooled score based on the intensity represented in
the majority of cancer cells. When one core was classified
as negative and the other core was classified as positive,
the pooled score was classified as positive. Only 22 tumors
showed strong intensity of HMGCR expression, and this
group was combined with tumors expressing HMGCR
with a moderate intensity (n = 195). A total of 28 of the
1,026 patients had bilateral tumors; tissue from both
tumors was available for 15 patients. Scoring of both
bilateral tumors was possible for 10 of these patients.
For the three cases where the intensity differed, the
highest intensity was used. In most cases (94.9 %) for
which the staining was positive in any cell, HMGCRwas expressed in the majority of the cells (51-100 %).
Therefore, the fraction of HMGCR-positive cells was
excluded from further analyses.
Statistics
The statistical analyses were performed using SPSS Statis-
tics 19 (IBM, Chicago, IL, USA). Patient and tumor charac-
teristics were analyzed in relation to HMGCR expression.
The Chi-square and Linear-by-Linear tests were used for
categorical variables. The Kruskal-Wallis and Jonckheere-
Terpstra tests were used for continuous variables because
some of these variables were not normally distributed.
Tumor characteristics in relation to HMGCR tumor
expression were also analyzed with linear regression and
adjusted for age as a continuous variable. The DFS was
calculated from the date of inclusion until the first breast
cancer related event (i.e., local or regional recurrence,
contralateral breast cancer, or distant metastasis); in cases
with no breast cancer related events, DFS was calculated
using the last study follow-up or death before July 1st,
2014. Non-breast cancer-related death was censored at the
time of death. Patients with distant metastases detected
earlier than three months after inclusion were excluded
from the survival analyses (n = 8). Univariable survival ana-
lyses were calculated using Log-Rank tests. Cox propor-
tional hazard regression was used for multivariable testing,
with adjustments for invasive tumor size (>20 mm or
muscular or skin involvement), axillary lymph node
involvement, histological grade (III), ER and PgR status
(positive/negative), age <50 years (yes/no), current pre-
operative smoking (yes/no), and body mass index
(BMI) <25 kg/m2 (yes/no) [27]. All statistical tests were
two-tailed. P-values < 0.05 were regarded as statistically
significant. Nominal P-values were presented without
adjustment for multiple testing.
Fig. 2 Examples of HMGCR expression, representing no staining (a), and weak (b), moderate (c), and strong (d) expression. The original magnification
before scale-down was 20x for each example
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Patient characteristics and HMGCR expression
The patient characteristics are presented in relation to
the HMGCR expression (Table 1). Of the 885 cases eva-
luable for scoring, the intensity of HMGCR expression
was negative in 113 cases (12.8 %), weak in 555 cases
(62.7 %), and moderate/strong in 217 (24.5 %) cases.
Patients of all ages were included (range 24–99 years).
The median age at inclusion in the study was 61.1 years
(interquartile range 52.1 to 68.1). Patients younger than
50 years at inclusion were significantly taller, had a lower
BMI, and had smaller waist and hip circumferences,
waist-to-hip ratios, and breast volumes than older
patients (P ≤ 0.001 for all comparisons); however, these
patients had a weight similar to that of older patients.
The final surgery performed included partial mastec-
tomy in 531 cases (60 %) and modified radical mastec-
tomy in 354 cases (40 %). Postoperative radiotherapy
was given to 559 patients (63.2 %) and 226 patients
(25.5 %) received adjuvant chemotherapy. As adjuvant
endocrine therapy, tamoxifen treatment was prescribed
to 466 patients (52.7 %) and 302 patients (34.1 %) weretreated with aromatase inhibitors. As of November 2005,
55 patients (8.6 %) had received adjuvant treatment with
trastuzumab (n = 640). Patients often received more than
one type of treatment.
Patients with tumors that expressed moderate/strong
HMGCR were significantly older than patients in the
other HMGCR intensity groups at inclusion. Patients
with tumors that expressed weak HMGCR were signifi-
cantly taller than patients in the other HMGCR intensity
groups. No other significant associations were observed
between patient characteristics and HMGCR expression.
The results remained essentially the same when exclud-
ing patients who reported statin usage preoperatively
(n = 99).
HMGCR expression and established tumor characteristics
Table 2 displays the tumor characteristics in relation to
HMGCR expression. Tumor size was not associated with
HMGCR expression. Tumors that expressed moderate/
strong HMGCR were of significantly lower histological
grade, were more frequently ER-positive, PgR-positive, and
HER2-negative, and were less likely to show axillary lymph





HMGCR expression-Intensity median (IQR) or %
No staining = 0 Weak = 1 Moderate/Strong
= 2/3
P-value
n= 1026 885 113 555 217
Age at inclusion, yrs 61.1 (52.1-68.1) 0 60.9 (52.2-67.9) 61.2 (53.7-69.2) 60.1 (51.6-67.4) 64.3 (53.9-69.4) 0.004c
Body mass index (BMI), (kg/m-2) 25.1 (22.5-28.3) 28 25.2 (22.5-28.4) 25.7 (23.2-28.7) 25.0 (22.4-28.3) 25.3 (22.5-29.0) 0.39c
Height (cm) 165 (162–170) 26 165 (162–170) 164 (160–169) 166 (162–170) 165 (161–169) 0.03c
Weight (kg) 69 (62–78) 26 69 (62–78) 70 (62–79) 69 (62–78) 69 (61–80) 0.91c
Waist-Hip-Ratio 0.86 (0.81-0.9) 38 0.86 (0.81-0.90) 0.86 (0.81-0.92) 0.85 (0.80-0.90) 0.86 (0.81-0.90) 0.32c
Waist (cm) 87 (79–97) 38 87 (80–97) 89 (82–97) 87 (79–97) 89 (80–98) 0.24c
Hip (cm) 102 (97–109) 38 102 (97–109) 104 (99–109) 102 (97–109) 102 (96–111) 0.57c
Breast volume (ml) 1000 (650–1500) 161 1000 (650–1550) 1000 (700–1550) 950 (640–1500) 1000 (656–1600) 0.28c
Age at menarche, yrs 13 (12–14) 7 13 (12–14) 13 (13–14) 13 (12–14) 13 (12–14) 0.68c
Nulliparous 124 (12.1 %) 1 109 (12.3 %) 17 (15.0 %) 67 (12.1 %) 25 (11.5 %) 0.41d
Parity 2 (1–3) 1 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–2) 0.46c
Age at first child, years* 25 (22–28) 6 24 (22–28) 24 (21–27) 25 (21–28) 25 (22–29) 0.09b
Ever use of HRT 449 (43.9 %) 3 386 (43.8 %) 55 (48.7 %) 231 (41.8 %) 100 (43.8 %) 0.28a
Ever oral contraceptives 726 (70.8 %) 1 625 (70.7 %) 82 (72.6 %) 394 (71.1 %) 149 (68.7 %) 0.42d
Current smoker 210 (20.5 %) 2 177 (20.0 %) 26 (23.0 %) 111 (20.1 %) 40 (18.4 %) 0.34d
Coffee, 2+ cups per day 832 (81.4 %) 4 708 (80.4 %) 89 (78.8 %) 448 (81.3 %) 171 (78.8 %) 0.66a
Alcohol abstainer 107 (10.5 %) 7 96 (10.9 %) 15 (13.3 %) 56 (10.1 %) 25 (11.6 %) 0.58a
*Among Parous women, IQR = Inter quartile range aChi-Square, bJonckheere-Terpstra, cKruskal-Wallis, dLinear-by-linear
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had weak or no HMGCR expression. Histological type
was not associated with HMGCR expression. HER2
amplification was more common among patients with
HMGCR-negative tumors. These associations remained
significant after adjustment for age. The results remained
essentially the same after exclusion of patients with
preoperative statin usage. Ki67 was only available for
365 patients (41.2 %) and was not further analyzed.
Risk of early breast cancer related events
Patients were followed for up to 11 years. The median
follow-up time was 5.0 years (interquartile range 3.0-
7.2 years) for the 739 patients who were alive and still at
risk at the last follow-up. The total number of patients
with a breast cancer related event during follow-up was
104, of whom 68 patients were diagnosed with distant
metastases. Of these 104 patients with a breast cancer
related event, 53 patients subsequently died during
follow-up. An additional 34 patients died without a prior
recorded breast cancer related event. No significant
association was observed between HMGCR expression
and DFS either in univariable (Log-Rank Ptrend = 0.42)
(Fig. 3) or or multivariable models (Table 3). Likewise,
no difference in DFS was observed between patients
with any HMGCR expression and patients with
HMGCR-negative tumors (Log-Rank Ptrend = 0.90). Inaddition, no significant association was observed
between HMGCR expression and distant metastasis-free
survival (Log-Rank Ptrend = 0.44), or overall survival
(Log-Rank Ptrend = 0.87). The results remained essentially
the same in analyses restricted to patients with ER-
positive tumors. Further stratification according to ER
status, treatment (e.g., tamoxifen, aromatase inhibitors,
radiotherapy, or chemotherapy), age or BMI failed to
yield any significant associations between HMGCR ex-
pression and DFS in either univariable or multivariable
models. The results remained essentially the same when
excluding preoperative statin users. Similarly, the results
did not differ when three patients with in situ breast
cancer related events were excluded.
Discussion
The main finding of this study was that moderate/strong
HMGCR expression was significantly associated with
several indolent tumor characteristics, including lower
histological grade, ER and PgR positivity, HER2 negativ-
ity, and less axillary lymph node involvement. These
findings are largely consistent with a previous study that
reported an association between stronger HMGCR ex-
pression and small tumor size, low histological grade,
low Ki67, and ER expression [1]. However, in the present
study, no association was observed between tumor size
and HMGCR expression, and Ki67 was not included in





HMGCR expression-Intensity median (IQR) or %
No staining = 0 Weak = 1 Moderate/Strong = 2/3 P-value
n= 1026 885 113 555 217
pT 0 0.77a
1 740 (72.1 %) 631 (71.3 %) 77 (68.1 %) 404 (72.8 %) 150 (69.1 %)
2 269 (26.2 %) 238 (26.9 %) 34 (30.1 %) 140 (25.2 %) 64 (29.5 %)
3 15 (1.5 %) 14 (1.6 %) 2 (1.8 %) 9 (1.6 %) 31 (1.4 %)
4 2 (0.2 %) 2 (0.2 %) 0 (0 %) 2 (0.4 %) 0 (0 %)
Axillary node involvement 2 0.020b
0 627 (61.2 %) 532 (60.2 %) 60 (53.1 %) 330 (59.6 %) 142 (65.7 %)
1-3 306 (29.9 %) 270 (30.6 %) 37 (32.7 %) 177 (31.9 %) 56 (25.9 %)
4+ 91 (8.9 %) 81 (9.2 %) 16 (14.2 %) 47 (8.5 %) 18 (8.3 %)
Histological grade 1 0.013b
I 252 (24.6 %) 203 (22.9 %) 20 (17.7 %) 126 (22.7 %) 57 (26.3 %)
II 511 (49.9 %) 443 (50.1 %) 54 (47.8 %) 278 (50.1 %) 111 (51.2 %)
III 262 (25.6 %) 239 (27.0 %) 39 (34.5 %) 151 (27.2 %) 49 (22.6 %)
Histological type 1 0.512a
Mainly ductal 836 (81.6 %) 737 (83.4 %) 96 (85.0 %) 467 (84.3 %) 174 (80.2 %)
Mainly lobular 121 (11.8 %) 97 (11.0 %) 11 (9.7 %) 55 (9.9 %) 31 (14.3 %)
Other or mixed 66 (6.4 %) 50 (5.7 %) 6 (5.3 %) 32 (5.8 %) 12 (5.5 %)
Hormone receptor status 2
ER+ 896 (87.5 %) 771 (87.2 %) 84 (74.3 %) 484 (87.4 %) 203 (93.5 %) <0.0001b
PgR+ 726 (70.9 %) 627 (70.9 %) 70 (61.9 %) 389 (70.2 %) 168 (77.4 %) 0.003b
HER 2 amplification* 59 0.009b
HER 2 positive 86 (11.7 %) 71 (11.1 %) 13 (21.0 %) 46 (11.2 %) 12 (7.2 %)
HER 2 negative 601 (81.4 %) 527 (82.3 %) 47 (75.8 %) 340 (82.7 %) 140 (83.8 %)
*Patients younger than 70 years of age and included as of November 2005 aChi-Square, bLinear-by-linear
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until March 2009 [28].
Patients with tumors that expressed moderate/strong
HMGCR were significantly older at the time of inclusion
in the present study, and only one of the patients with
strong HMGCR staining was less than 50 years of age.
This finding is consistent with another study that studied
premenopausal patients and reported no tumors with
strong expression of this marker [3]. ER-positive tumors
are more common in postmenopausal patients than in
premenopausal patients [29]. In the present study, moder-
ate/strong HMGCR expression was associated with ER
positivity, indicating that there might be an association be-
tween age, HMGCR expression and ER-positive tumors.
This association may be linked to 27-hydroxycholesterol
(27HC), which is a primary cholesterol metabolite and a
selective estrogen receptor modulator (SERM) exerting ER
agonistic effects, as recently shown in a study of murine
models [30, 31]. The study demonstrated how conversion
of cholesterol to 27HC was necessary for effects on ER-
positive breast cancer cells and how the actions of 27HCon tumor growth were dependent on ER. Those findings
shed light on how 27HC may promote cancer growth and
serve as the link between hypercholesterolemia and ER-
positive breast cancer in postmenopausal women.
Normal cells can obtain cellular cholesterol in two ways;
either via receptor-mediated uptake (low-density-lipopro-
tein receptor) or by synthesizing cholesterol through the
mevalonate pathway and the activity of HMGCR. The
normal cellular response to low intracellular cholesterol
levels is to increase HMGCR activity to maintain an intact
mevalonate pathway. However, tumor cells that fail to
respond to this feed-back loop might have lost the
checkpoint controls that maintain an intact pathway or
may have a deregulated pathway [1, 32]. This dysregula-
tion of the mevalonate pathway and HMGCR activity can
contribute to the transformation involved in oncogenesis
and may be essential for the metabolic transformation
of tumor cells, at least in some cancers [32]. Therefore,
potential biomarkers within the mevalonate pathway
that could predict the response to statin treatment are
of interest.
Strong/Moderate n=   213   208    189    147      98       92       62       61      25      23       7      3 
Weak n=                     552   521    470    375    281     264     176     168      88     84      23      8
No Staining n=           112    109    101     80      58       57       46       43      32      28      11      7
HMGCR expression 








Fig. 3 Kaplan-Meier estimate of DFS in relation to HMGCR expression. The number of patients at each follow-up is indicated. Since this study is
an on-going study, the number of patients decreases with each follow-up
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cancer is less likely to arise among statin users and that
ER-negative cell lines are more sensitive to statin inhib-
ition than ER-positive cell lines [33]. In the present study,
tumors that were negative for both ER and HMGCR
had a higher histological grade significantly more often
than tumors that were positive for these markers (data
not shown). This association may reflect an inability of
less differentiated cancer cells to maintain an intact











Preoperative smokersome cancer cells could be statin-sensitive and unable to
maintain adequate levels of mevalonate end products when
exposed to statins, resulting in apoptosis [32]. In contrast,
statin-insensitive tumor cells demonstrate a feedback re-
sponse similar to that of normal cells, in which HMGCR is
up-regulated; this response may protect these cells from
the anticancer effects of statins [32]. It is possible that well-
differentiated cancer cells but not less differentiated cancer
cells are capable of initiating this response. Further studies
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HMGCR expression and DFS in the present study. Two
previous studies reported associations between recurrence-
free survival and HMGCR expression [2, 3]. However, the
median follow-up time of the present study was only
5.0 years, compared to median follow-up times of 10.7 years
[2] and 13.9 years [3] in the previous studies. Moderate/
strong HMGCR expression was strongly associated with
ER-positive tumors. ER-positive tumors are known to
relapse later than ER-negative tumors; because 87.5 % of
the patients in the present study had ER-positive tumors, a
longer follow-up time may be needed [34].
HMGCR expression was negative in 12.8 % of the
cases in this study. The percentage of tumors with nega-
tive staining varied between 18 % and 52.7 % of cases in
previous studies [1–3, 35]. However, these studies had
fewer tumors that stained for HMGCR. In addition, one
study included only premenopausal patients [3], which
may have affected the results because HMGCR was
significantly associated with age in the present study.
Although the intensity varied between studies, the
finding in the current study that HMGCR is expressed
in the majority of the cells when present is consistent
with other studies [2, 3].
HMGCR is differentially expressed and often overex-
pressed in tumor cells [18] and high expression appears
to be associated with less aggressive tumor characteristics
[1, 2]. Previous studies reported that HMGCR expression
was a good prognostic marker [2, 3]. A previous window-
of-opportunity study demonstrated that patients who were
treated with statins for two weeks pre-operatively exhibited
increased expression of HMGCR in the tumor and a
reduced proliferation rate of Ki67 [35]. The increase of
HMGCR expression that occurs after statin treatment indi-
cate that statins affected the tumor either directly through
inhibition of HMGCR and the mevalonate pathway within
the tumor or indirectly through lowered circulating levels
of cholesterol and in both cases, a negative feed-back loop
resulting in elevated intratumoral HMGCR levels [32].
Associations of HMGCR expression with more favorable
tumor characteristics and a prolonged survival have also
been demonstrated in patients with other types of cancer
such as colorectal cancer [36].
Some limitations of this study should be considered. One
weakness of the present study may be that HMGCR
expression was evaluated on TMAs rather than in whole
slide tumor tissue sections. However, a previous study
stained five whole slide tumor tissue sections for HMGCR
and this marker was homogeneously expressed in all of the
sections [1]. Therefore, we believe that the HMGCR results
obtained from TMAs are representative. The BC-blood
study is an ongoing, population-based prospective study,
which limits the risk for recall bias. The most common
reason that patients did not participate in the present studywas the lack of available research nurses. A previous study
demonstrated that the patients who did not participate had
patient and tumor characteristics similar to those who
did participate [28]. This similarity makes the findings
generalizable for breast cancer patients at Skåne University
Hospital in Lund, Sweden. The patients were never asked
about ethnicity. However, the majority of the patients were
ethnic Swedes. To the authors’ knowledge, the variation of
HMGCR expression in cancer cells among different ethnic
groups has not been investigated previously.
In conclusion, high HMGCR expression appears to be
associated with less aggressive tumor characteristics in
this population-based cohort of unselected primary
breast cancer patients. Despite this finding, no associ-
ation between HMGCR expression and short-term DFS
was observed. Since previous studies had longer follow-
up times, their findings can be neither confirmed nor
rejected. Further studies and a prolonged follow-up time
are needed to evaluate HMGCR as a prognostic and
treatment-predictive marker.
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